Sherwin Arman
Orofacial Pain · Los Angeles, CANPI 1821135138
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $354 of the $470 with a category attached, or 75.3%. It is spread thinly across 9 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $222 and has fallen 86.0% since, to $31 in 2024.
Across 14 payments — averaging $33.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz Pharmaceuticals, LLC$112
- Amgen$87
- Teva Pharmaceuticals USA, Inc.$62
- AbbVie$49
- Impel Pharmaceuticals Inc.$36
- Johnson & Johnson$35
- plus $88 from 3 others
What the payments were for
- Food & beverage$35475%
- Education$11625%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz Pharmaceuticals, LLC | 2 | $112 |
| Amgen | 3 | $87 |
| Teva Pharmaceuticals USA, Inc. | 2 | $62 |
| AbbVie | 2 | $49 |
| Impel Pharmaceuticals Inc. | 1 | $36 |
| Johnson & Johnson | 1 | $35 |
| Lilly USA, LLC | 1 | $31 |
| Biolase, Inc. | 1 | $30 |
| Lundbeck LLC | 1 | $26 |
How this compares
Too few orofacial pain providers in Californiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 14 | $9,860 |
| Gabapentin | 58 | $1,010 |
| Carbamazepine | 11 | $960 |
| Lidocaine Hcl ViscousLidocaine Hcl | 41 | $363 |
| Duloxetine Hcl | 11 | $252 |
| Baclofen | 17 | $164 |
Paid to pharmacies, not to this prescriber.
Other orofacial pain in Los Angeles
- Katayoun OmraniLos Angeles$4K
- Victoria WexleyLos Angeles$3K
- Alan NewmanLos Angeles$1K
- Mohammad KhalifehLos Angeles$258
- Suzan SabaghLos Angeles$144
- Jeffrey WeberLos Angeles$32
- Brigitte LovellOjai$290K
- Ali MakkiIrvine$86K
- Rich HirschingerBeverly Hills$4K
- Rashpal DeolSan Ramon$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.